The spiraling problem of drug resistance has necessitated the development of novel antibiotics. AbGenics is developing  antibody based antibiotics particularly directed against the most serious pathogens: the ESKAPE pathogens, that is prevalent in hospital settings, fungi that cause persistent dermal infections and enteric bacteria that cause epidemics under conditions of natural calamities.

We have developed CaMabs (see table below) to address these issues and has the potential to supplement or replace antibiotic usage.

  • ESKAPE CaMabs: Antibodies against serious pathogens like Enterobacter, Streptococcus, Klebsiella, Acinetobacter, Pseudomonas, Enterococcus can be used for therapy (burns, diabetic foot and trauma) or for diagnostic applications (sepsis). They can be used to neutralize pathogens in surgical implants and catheters, and as sanitizing agents in hospitals and clean rooms.
  • Candida and Malassezia CaMabs : For topical use to control fungal skin infections. They are being formulated as lotions and shampoos to control eczema hair fall and dandruff.
  • E coli, Salmonella and Clostridia CaMabs: For controlling enteric infections. Can be used for human and animal healthcare applications. The antibodies are being secreted and surface displayed by gut colonizing Lactobacilli for control of persistent infections.


AbGenics is developing a new class of antibiotics called AbTids® in which antimicrobial peptides are being combined with CaMabs using labile linkers  by genetic engineering techniques. The antimicrobial peptides are released on the surface of the pathogen resulting in their rapid lysis and neutralization.